Burzynski: Japan antineoplaston publications

7/20/1988 – Chemopreventive effect of antineoplaston A-10 on urethane-induced pulmonary neoplasm in mice
http://www.ncbi.nlm.nih.gov/m/pubmed/3183462
Tsuda
N E
Nihon Gan Chiryo Gakkai Shi. 1988 Jul.20; 23 (7):1560-5
23(7):1560-5 (1988)
Nihon Gan Chiryo Gakkai Shi

1/20/1990 – A-10 Injection – The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice
http://www.ncbi.nlm.nih.gov/m/pubmed/2157780
Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):1-5
1990 Tsuda (Japan) et al published with The members of Antineoplaston Study Group
Kurume Med J. 1990;37(2):97-104
http://www.ncbi.nlm.nih.gov/pubmed/2175003
Burzynski References: 1 – 8 and 11 – 14
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_pdf
5/1992 Tsuda (Japan) publishes re A-10 Injection:
http://www.ncbi.nlm.nih.gov/m/pubmed/1377669
Burzynski References: 1, 4 – 7 and 9
Nishida (Japan) A-10 Reference: 2
Abstract:
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract
References:
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/references
PDF
http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hdcl29bl&s=dd78f02b92e0f5544c136e7b897a7d65bcf5dc71&systemMessage=Wiley+Online+Library+will+be+disrupted+on+23+February+from+10%3A00-12%3A00+BST+%2805%3A00-07%3A00+EDT%29+for+essential+maintenance
5/1995 Tsuda (Japan) publishes re Antineoplaston:
Kurume Med J. 1995;42(3):133-40
http://www.ncbi.nlm.nih.gov/m/pubmed/7474850
Burzynski References: 1 – 2 and 4
Samid Reference: 7 (who learned from Burzynski re Phenylacetate)
Lee (Japan) A-10 Reference: 3
Nishidi (Japan) A-10 Reference: 6
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/3/42_3_133/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/3/42_3_133/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/3/42_3_133/_pdf
1995 Tsuda (Japan) publishes re A-10 and AS2-1:
Kurume Med J. 1995;42(4):241-9
http://www.ncbi.nlm.nih.gov/m/pubmed/8667595
Burzynski References: 1 – 3 and 5
Nishida et al. (Japan) A-10 Reference: 4 and 7
Muldoon et al. A-10 Reference: 6
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_pdf
1996 Tsuda (Japan) publishes re A10 and AS2-1:
Kurume Med J. 1996;43(2):137-47
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
Burzynski References: 1 – 3, 5 and 7
Samid Reference: 13 (who learned from Burzynski re Phenylacetate)
Nishida et al. (Japan) A10 Reference: 4 and 10
Muldoon et al. A10 Reference: 8
Abstract:
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article
References:
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article/references
PDF
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf
7 – 8/2007 (Japan) publishes re A10:
http://www.ncbi.nlm.nih.gov/m/pubmed/17695534
Burzynski References: 1, 3, 5, 13 and 15
Badria (Egypt) A-10 References: 2 and 20
Wang A10 Reference: 4
http://ar.iiarjournals.org/content/27/4B/2427.short
Abstract:
http://ar.iiarjournals.org/content/27/4B/2427.long
PDF
http://ar.iiarjournals.org/content/27/4B/2427.full.pdf
1/2008 (Japan) publishes re antineoplaston:
Breast Cancer. 2008;15(1):73-8. doi: 10.1007/s12282-007-0015-y
Breast Cancer: January 2008, Volume 15, Issue 1, pp 73-78
http://www.ncbi.nlm.nih.gov/m/pubmed/18224398
Burzynski Reference: 12
Tsuda (Japan) Antineoplaston Reference: 13
http://link.springer.com/article/10.1007%2Fs12282-007-0015-y

1990 – Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines
http://www.ncbi.nlm.nih.gov/m/pubmed/2175003
H TSUDA
Kurume University School of Medicine, Japan
Kurume Med J 37 (2):97-104 (1990)
Kurume Medical Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/37/2/37_2_97/_article

http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract

http://ci.nii.ac.jp/naid/130000888719

1991 – Inhibitory effect of orally administered antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice
J Jpn Soc Cancer Ther 26:595-601, 1991

1992 – antineoplaston – Prevention of drug induced DNA hypermethylation by antineoplaston components
LIAU M C
Intl J Exp Clin Chemother 1992; 5:19-27
https://data.epo.org/publication-server/pdf-document?PN=EP0680756%20EP%200680756&iDocId=4830495&iepatch=.pdf

http://eng.med.wanfangdata.com.cn/PaperDetail.aspx?qkid=zgzllc-e&qcode=zgzllc-e200504004

http://so.med.wanfangdata.com.cn/ViewHTML/PeriodicalPaper_zgzllc-e200504004.aspx

5/1992 – The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/1377669
The Inhibitory Effect of the Combination of Antineoplaston A-10 Injection with a Small Dose of cis-Diamminedichloroplatinum on Cell and Tumor Growth of Human Hepatocellular Carcinoma
H TSUDA
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken
Jpn J Cancer Res. 1992 May;83(5):527-31
Jpn. J. Cancer Res. 83, 527-531
Jpn J Cancer Res. 1992 May;83 (5):527-31
Jpn J Cancer Res 83 (5):527-31 (1992)
Article first published online: 26 AUG 2005
DOI: 10.1111/j.1349-7006.1992.tb01960.x
Japan Journal Cancer Research
http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1992.tb01960.x/abstract

http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf?v=1&t=hd97ht7z&s=3481466c7830e5f8e2bb925a698de6f8155da747

http://onlinelibrary.wiley.com/store/10.1111/j.1349-7006.1992.tb01960.x/asset/j.1349-7006.1992.tb01960.x.pdf;jsessionid=4ECD3F595A3971B5AB87763862867844.d03t02?v=1&t=hbmd55gj&s=a14b626a37db3ecd558109cee30dfe26c71827763862867844
Cancer Science
Cancer …, Wiley Online Library
2003 – AS2-1 –
Oncology …,
The preventive effect of antineoplaston AS2-1 on HCC recurrence

1995 – (Clinically tested) – The effect of Antineoplaston, a new antitumor agent on malignant brain tumors
http://www.ncbi.nlm.nih.gov/m/pubmed/7474850
H H TSUDA
Department of Neurosurgery, Kurume University School of Medicine, Japan
Kurume Med J. 1995;42(3):133-40
Kurume Med J 42(3):133-40 (1995)
Kurume Medical Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic

1995 – Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients
http://www.ncbi.nlm.nih.gov/m/pubmed/8667595
H Tsuda
Kurume Med J 42 (4):241-9 (1995)
Department of Anesthesiology, Kurume University School of Medicine, Japanu
Kurume Med Journal
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/42/4/42_4_241/_pdf

1996 – Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
Tsuda H
Department of Anesthesiology, Kurume University School of Medicine, Japan
Kurume Med J 43 (2):137-47 (1996)
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf

11-12/1997 – phase I clinical trial – Antineoplaston AS2-1 for maintenance therapy in liver cancer
http://www.ncbi.nlm.nih.gov/m/pubmed/21590224
H Tsuda
http://www.ncbi.nlm.nih.gov/m/pubmed/21590224
KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA,JAPAN. KURUME UNIV,SCH MED,DEPT RADIOL,KURUME,FUKUOKA,JAPAN
4 (6):1213-6
Oncol Rep. 1997 Nov-Dec;4(6):1213-6
Oncol Rep. 1997; 4:1213- 1216
Oncol Rep 4 (6):1213-6 (1997)
Oncology Reports
http://www.spandidos-publications.com/or/4/6/1213

5 – 6/1998 – A10 and AS2-1 – I – Quick response of advanced cancer to chemoradiation therapy with antineoplastons
http://www.ncbi.nlm.nih.gov/m/pubmed/9538158
H Tsuda
http://www.ncbi.nlm.nih.gov/m/pubmed/9538158
Department of Anesthesiology, Kurume University, School of Medicine, Kurumeshi, Fukuokaken, Japan
5 (3):597-600
Oncol. Rep. 1998;5:597–600
Oncol Rep. 1998 May-Jun;5 (3):597-600
Oncol Rep 5 (3):597-600 (1998)
Oncology Reports
http://www.spandidos-publications.com/or/5/3/597

11-12/1998 – A10 I – I – Antineoplaston treatment for advanced hepatocellular carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/9769368
H Tsuda
Department of Radiology, Kumabe Hospital, Kurume University School of Medicine, Kurumeshi, Fukuokaken, Japan
5 (6):1363-7
Oncol Rep. 1998;5:1363-1367
Oncol Rep. 1998 Nov-Dec;5 (6):1363-7
Oncol Rep 5 (6):1363-7 (1998)
Oncology Reports, Spandidos Publications
http://www.spandidos-publications.com/or/5/6/1363

2002 – Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma
H TSUDA
Department of Anesthesiology, Kurume University School of Medicine, Japan
43 (2):137-47 PMID 8755117
J-STAGE, Japan Science and Technology Information Aggregator, Electronic
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf

2002 – A10 & AS2-1 – A novel strategy for remission induction and maintenance in cancer therapy
http://www.ncbi.nlm.nih.gov/m/pubmed/11748457
H Tsuda
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken , Japan
mx2.tiki.ne.jp
Oncol Rep 2002;9:65–8
Oncol. Rep. 2002;9:65-68
Oncol Rep 9(1):65-8 (2002)
Oncology Reports, Spandidos Publications
http://www.spandidos-publications.com/or/9/1/65

2002 -The preventive effect of antineoplaston AS2-1 on HCC recurrence
Tsuda
Oncology Reports 2002; 10: 391-397
http://www.burzynskiclinic.com/images/stories/Publications/964.pdf

2003 – Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case
http://www.ncbi.nlm.nih.gov/m/pubmed/12768372
TSUDA H
Surg Today 2003
http://www.springerlink.com/content/b48ch3ha165nbrqp

http://sciencelinks.jp/j-east/article/200313/000020031303A0389449.php

http://ci.nii.ac.jp/naid/10015483373

3 – 4/2003 – Phase II Clinical Trial – The preventive effect of antineoplaston AS2-1 on HCC recurrence
http://www.ncbi.nlm.nih.gov/m/pubmed/12579278
Hideaki H TSUDA
Department of Anesthesiology, Kurume Daiichi Social Insurance Hospital, Kushihara Kurumeshi, Fukuoka, Japan
Oncol Rep. 2003 Mar-Apr;10(2):391-7
Oncol Rep 10 (2):391-7 (2003)
Oncol Rep 2003;10:391–7
Oncol Rep. 2003;10:391-397
Oncology Reports
Spandidos Publications
http://www.spandidos-publications.com/or/10/2/391

http://link.springer.com/article/10.1007%2Fs10595-002-2503-2?LI=true

6/2003 – A10 & AS2-1 – Phase II Clinical Trial – Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases:
Report of a Case
http://www.ncbi.nlm.nih.gov/m/pubmed/12768372
Hideaki Tsuda
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
Surg Today. 2003;33(6):448-53
Surg Today 2003; 33:448–53
Surg Today. 2003; 33:448-453
33 (6):448-53
DOI: 10.1007/s10595-002-2503-2
Surgery Today, Springer

http://link.springer.com/article/10.1007%2Fs10595-002-2503-2

http://link.springer.com/article/10.1007%2Fs10595-002-2503-2?LI=true

http://link.springer.com/content/pdf/10.1007%2Fs10595-002-2503-2

http://sciencelinks.jp/j-east/article/200313/000020031303A0389449.php

http://ci.nii.ac.jp/naid/10015483373

9/2003 – [Anti-proliferative effects of biochemical defense modifier antineoplaston in colorectal carcinoma]
http://www.ncbi.nlm.nih.gov/m/pubmed/14574945
Department of Surgery, Kurume University School of Medicine
61 Suppl 7:505-9
Nihon Rinsho (2003)
Nihon Rinsho. 2003 Sep; 61 Suppl 7:505-9 Article in Japanese

2004 -Analysis of cell growth inhibitory effects of antineoplaston through MAPK in human breast cancer cell line SKBR-3
http://www.ncbi.nlm.nih.gov/m/pubmed/14755017
TSUDA
EJC Supplements 2 (3): 2 (2004),
DOI: 10.1016/S1359-6349(04)90794-X
The Oncologist, AlphaMed Press
Complementary and alternative therapies for cancer
http://m.theoncologist.alphamedpress.org/content/9/1/80.short

http://theoncologist.alphamedpress.org

http://m.theoncologist.alphamedpress.org/content/9/1/80.long

http://m.theoncologist.alphamedpress.org/content/9/1/80.full.pdf

http://theoncologist.alphamedpress.org/content/9/1/80.full?sid=09bf7d6b-2d6c-4097-a48d-ef768e65569b

http://theoncologist.alphamedpress.org/content/9/1/80.full.pdf?sid=30deadf2-7850-4ea2-9760-664ceee77eed

http://www.oncocure.ca/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

http://intl-cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://www.integratedhealthclinic.com/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

http://theoncologist.alphamedpress.org/content/9/1/80.full?sid=09bf7d6b-2d6c-4097-a48d-ef768e65569b

http://theoncologist.alphamedpress.org/content/9/1/80.full.pdf?sid=30deadf2-7850-4ea2-9760-664ceee77eed

http://www.oncocure.ca/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

http://intl-cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://cme.alphamedpress.org/cgi/hierarchy/ampcme_course;91080

http://www.integratedhealthclinic.com/assets/byTopic/IntegrativeOncology/2-CAM%20Therapies%20in%20CA-Oncologist%202004.pdf

2005 – Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat
http://www.ncbi.nlm.nih.gov/m/pubmed/15706406
Tsuda H
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Oncol Rep. 2005 Mar;13(3):389-95
Oncology …,

3/2005 – Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat
http://www.ncbi.nlm.nih.gov/m/pubmed/15706406
Hideaki TSUDA
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Oncol Rep 13 (3): 389-95 (2005)
Oncol Rep. 2005 Mar; 13 (3):389-95
Oncology Reports, 3/2005, Volume 13 Number 3
Pages: 389-395 Oncology Reports, Spandidos Publications
http://www.spandidos-publications.com/or/13/3/389

8/2005 – Antineoplaston A10 – Antineoplaston induces G1 arrest by PKCα and MAPK pathway in SKBR-3 breast cancer cells
http://www.ncbi.nlm.nih.gov/m/pubmed/16012735
Antineoplaston induces G1 arrest by PKCo and MAPK pathway in SKBR-3 breast cancer cells
Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells
Hideaki H TSUDA
Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan
med.kurume-u.ac.jp
Oncol Rep 14(2):489-94 (2005)
Oncol Rep. 8/2005; 14(2):489-94
Oncology Reports, 8/2005, Volume 14 Number 2
Pages: 489-494
Oncol Rep. 2005; 14:489–94
Oncol. Rep. 14, 489–494
Oncology .Reports, Spandidos Publications
http://www.spandidos-publications.com/or/14/2/489

http://gyouseki.kurume-u.ac.jp/PDF/ichiran_2005.pdf

http://research.kurume-u.ac.jp/K90RES.php?scode=49485632873864

http://onlinelibrary.wiley.com/doi/10.1002/iub.574/abstract

http://onlinelibrary.wiley.com/doi/10.1002/iub.574/full

http://onlinelibrary.wiley.com/store/10.1002/iub.574/asset/574_ftp.pdf?v=1&t=hbr9z60q&s=0b1c1e8655db9c54b45dbf72062e8b11cb7895ac

2006 – Inhibitory Effect of Antineoplaston A10 and AS2-1 on Human Hepatocellular Carcinoma
http://www.ncbi.nlm.nih.gov/m/pubmed/8755117
TSUDA
med.kurume-u.ac.jp
Kurume Medical Journal
http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_article

http://www.jstage.jst.go.jp/article/kurumemedj1954/43/2/43_2_137/_pdf

7 – 8/27/2007 – Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10
http://www.ncbi.nlm.nih.gov/m/pubmed/17695534
Induction of Apoptosis in Human Hepatocellular Carcinoma Cells by Synthetic Antineoplaston A10,
School of Pharmaceutical Sciences, Shandong University, Jinan, Japan
Anticancer Research, Vol. 27, No. 4B, 2007, pp. 2427-2431
Anticancer Res 27(4B):2427-31 (2007)
Anticancer Res. 7 – 8/2007; 27(4B):2427-31
Anticancer Research
International Journal of Cancer Treatment
HighWire Press
http://ar.iiarjournals.org/content/27/4B/2427.short

http://ar.iiarjournals.org/content/27/4B/2427.long

http://ar.iiarjournals.org/content/27/4B/2427.full.pdf

http://www.iiar-anticancer.org/main.php?pid=3398&id=2&ch=52&gch=&volume=27&issue=4B&show=details&page=2

1/2008 – antineoplaston – Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancer
http://www.ncbi.nlm.nih.gov/m/pubmed/18224398
15(1):73-8
Department of Surgery, Kurume University, Fukuoka, Japan
Breast Cancer 15(1):73-8 (2008)
DOI: 10.1007/s12282-007-0015-y
http://link.springer.com/article/10.1007%2Fs12282-007-0015-y

http://www.springerlink.com/content/p724x34746l56v73

http://ci.nii.ac.jp/naid/10021288533

2010 – Antineoplastons – Japan – Tsuda – Phase II
Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer

Annals of Oncology 2010;21:viii221
http://www.burzynskiclinic.com/images/stories/Publications/8774.pdf

Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for liver Metastases from Colorectal Cancer
https://stanislawrajmundburzynski.wordpress.com/2013/03/28/burzynski-the-antineoplaston-randomized-japan-phase-ii-clinical-trial-study
Annals of Oncology 2010;21:viii221
http://www.burzynskiclinic.com/images/stories/Publications/8774.pdf

http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx

http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558
11. Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets

(May 27/09)

Positive results were borne from a phase II clinical study of Antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of liver mets

The study was performed in Japan

The study consisted of 65 colon cancer patients who had undergone curative resection of their liver mets and were randomized to one of the following groups:

1. intrahepatic infusion of 5FU

2. intrahepatic infusion of 5FU plus IV ANP therapy given (a) daily for seven days following hepatic
resection, and (b) ANP therapy given orally daily for one year

There was a significant difference in overall survival between the 2 groups, with the 5 year survival rate in the 5FU plus ANP therapy arm being 63% vs. 32% in the 5FU only arm

Recurrence rate also differed for the 2 groups, which were 34% and 69% respectively

Lead investigator claims that ANP therapy may find application not only in the treatment of brain tumors as reported previously, but also in the more common colorectal cancer
http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets

Randomized Phase II Study of Hepatic Arterial Infusion with or without Antineoplastons as Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer
http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx
Publication date: May 17, 2010
Category: Colorectal cancer
Publisher: ESMO
Y. Ogata; K. Shirouzu; K. Matono; M. Ushijima; S. Uchida; H. Tsuda
http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558
Abstract: 3558
Congress: ESMO 2010
Type: Publication
Topic: Colorectal cancer
Authors: Y. Ogata, K. Shirouzu, K. Matono, M. Ushijima, S. Uchida, H. Tsuda; Kurume/JP
http://www.biomeddefine.com/sdx/t31/all/100/epithelial+neoplasm+glandular+piperidines+chemical+ingredient.html

http://www.biomeddefine.com/sdx/t31/all/100/ca+secondary+cancer+piperidines+chemical+ingredient.html
Antineoplaston Therapy Doubles Five-Year Survival Rate Following Curative Resection of Hepatic Mets

Metastatic Colon Cancer:

In a Randomized Phase II Clinical Study, Antineoplaston Therapy Doubled the 5-Year Survival Rate Following Curative Resection of Hepatic Metastases
http://www.drugs.com/clinical_trials/metastatic-colon-cancer-randomized-phase-ii-clinical-study-antineoplaston-therapy-doubled-5-year-7307.html
HOUSTON–(BUSINESS WIRE)–May 27, 2009 – The Burzynski Research Institute, Inc.

(BRI) is pleased to announce the results of a randomized Phase II clinical study of antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of hepatic metastases

The study was performed at the Kurume University School of Medicine (Japan) in the Department of Surgery

A report of the study results is currently in press
http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx

http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558
11. Antineoplaston Therapy Doubles 5-Year Survival Rate Following Curative Resection of Hepatic Mets (May 27/09)
Positive results were borne from a phase II clinical study of Antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of liver mets
study was performed in Japan
study consisted of 65 colon cancer patients who had undergone curative resection of their liver mets and were randomized to one of the following groups:
1. infusion of x
2. infusion of x plus IV ANP therapy
significant difference in overall survival between the 2 groups
5 year survival rate
63% in x plus ANP therapy arm
32% in the x only arm
Recurrence rate for the 2 groups
34%
69%
http://finance.yahoo.com/news/Metastatic-Colon-Cancer-In-a-bw-15355368.html?.v=1

http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf

http://www.colorectal-cancer.ca/IMG/pdf/CCAC_Research_June_19_2009.pdf
Annals of Oncology 2010;21:viii221

http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2010/randomized-phase-ii-study-of-hepatic-ar-3558.aspx

http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=3558

http://www.biomeddefine.com/sdx/t31/all/100/epithelial+neoplasm+glandular+piperidines+chemical+ingredient.html

http://www.biomeddefine.com/sdx/t31/all/100/ca+secondary+cancer+piperidines+chemical+ingredient.html

http://www.drugs.com/clinical_trials/metastatic-colon-cancer-randomized-phase-ii-clinical-study-antineoplaston-therapy-doubled-5-year-7307.html

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s